Chronic HIV Infections Clinical Trial
Official title:
Safety and Efficacy of the Histone Deacetylase Inhibitor Chidamide in Combination With Antiretroviral Therapy for Eradication of the Latent HIV-1 Reservoir(CHARTER)
HIV replication can be effectively suppressed and acquired immunodeficiency syndrome(AIDS) can be prevented with highly active antiretroviral therapy (HAART). However, HIV-infected people must remain on treatment continuously to avoid viral rebound and progression to AIDS. HIV persistence is thought to stem primarily from the presence of integrated copies of the proviral genome within long-lived cells. Because active viral gene expression causes cell death due to viral cytopathic effects and the immune response, long-lived cells likely harbor transcriptionally silent, latent provirus. HIV-1 persistence in long-lived cellular reservoirs remains a major barrier to a cure. HDACi have the potential to activate ("Kick") these latently infected cells. This will make the HIV infected cells visible to the immune system; the immune response and antiretrovirals(ARVs) will be able to attack and eliminate ("Kill") the infected cells. The purpose of this study is to evaluate the safety and efficacy of multi-dose Chidamide in combination with antiretroviral therapy in HIV-infected adults with suppressed viral load.
Every participant will receive oral Chidamide on Day 0, 3, 7, 10, 14, 17, 21, 24. In Step 1,
the dose of Chidamide will be 10 mg each time, for Step 2 30 mg each time. Participants will
be enrolled into Step 1 first; if the dose given to Step 1 is well tolerated and no safety
concerns are noted, Step 2 will be enrolled. All participants will keep their antiretroviral
therapy during this study.
Each step of this study will last for 56 days, involving 14 study visits(Screening, Day 0, 2,
3, 8, 11, 14, 15, 17, 21, 24, 26, 27, 56) for every participant. At the screening visit,
participants will give a medical history and will undergo a physical exam; blood samples will
be collected. Participants will undergo pharmacokinetic (PK) sampling which will require that
blood be drawn at 0, 1, 2, 6, 12, 24, 48, 72h after the first dose. For multi-dose PK
studies, blood samples will be collected at the same time points after the last dose.
Participants will undergo pharmacodynamic (PD) sampling which will require that blood be
drawn at 0, 6, 12, 24, 48, 72h after the first dose. For steady-state concentration PK and PD
studies, blood samples will be collected 5-30 minutes before Chidamide administration on Day
14, 17, 21. If participants agree, their blood samples may be stored for future research.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02902185 -
Chidamide in Combination With ART for Reactivation of the Latent HIV-1 Reservoir
|
Phase 2/Phase 3 |